Pharmaniaga Berhad (KLSE:PHARMA)

Pharmaniaga Berhad Statistics

Total Valuation

KLSE:PHARMA has a market cap or net worth of MYR 1.64 billion. The enterprise value is 2.25 billion.

Market Cap	1.64B
Enterprise Value	2.25B

Important Dates

The last earnings date was Friday, May 15, 2026.

Earnings Date	May 15, 2026
Ex-Dividend Date	n/a

Share Statistics

KLSE:PHARMA has 6.56 billion shares outstanding. The number of shares has increased by 239.34% in one year.

Current Share Class	6.56B
Shares Outstanding	6.56B
Shares Change (YoY)	+239.34%
Shares Change (QoQ)	+81.43%
Owned by Insiders (%)	2.73%
Owned by Institutions (%)	11.84%
Float	2.07B

Valuation Ratios

The trailing PE ratio is 24.31 and the forward PE ratio is 15.31.

PE Ratio	24.31
Forward PE	15.31
PS Ratio	0.40
PB Ratio	3.35
P/TBV Ratio	5.23
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.53, with an EV/FCF ratio of -24.79.

EV / Earnings	44.57
EV / Sales	0.55
EV / EBITDA	14.53
EV / EBIT	18.23
EV / FCF	-24.79

Financial Position

The company has a current ratio of 0.92, with a Debt / Equity ratio of 1.63.

Current Ratio	0.92
Quick Ratio	0.53
Debt / Equity	1.63
Debt / EBITDA	5.17
Debt / FCF	-8.83
Interest Coverage	2.28

Financial Efficiency

Return on equity (ROE) is 28.41% and return on invested capital (ROIC) is 8.27%.

Return on Equity (ROE)	28.41%
Return on Assets (ROA)	3.43%
Return on Invested Capital (ROIC)	8.27%
Return on Capital Employed (ROCE)	18.95%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	1.16M
Profits Per Employee	14,392
Employee Count	3,502
Asset Turnover	1.80
Inventory Turnover	5.83

Taxes

In the past 12 months, KLSE:PHARMA has paid 23.02 million in taxes.

Income Tax	23.02M
Effective Tax Rate	30.43%

Stock Price Statistics

The stock price has decreased by -18.64% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-18.64%
50-Day Moving Average	0.25
200-Day Moving Average	0.25
Relative Strength Index (RSI)	40.13
Average Volume (20 Days)	8,909,585

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KLSE:PHARMA had revenue of MYR 4.05 billion and earned 50.40 million in profits. Earnings per share was 0.01.

Revenue	4.05B
Gross Profit	410.10M
Operating Income	123.24M
Pretax Income	75.64M
Net Income	50.40M
EBITDA	144.06M
EBIT	123.24M
Earnings Per Share (EPS)	0.01

Balance Sheet

The company has 217.30 million in cash and 799.81 million in debt, with a net cash position of -582.50 million or -0.09 per share.

Cash & Cash Equivalents	217.30M
Total Debt	799.81M
Net Cash	-582.50M
Net Cash Per Share	-0.09
Equity (Book Value)	489.50M
Book Value Per Share	0.07
Working Capital	-140.86M

Cash Flow

In the last 12 months, operating cash flow was -60.67 million and capital expenditures -29.94 million, giving a free cash flow of -90.61 million.

Operating Cash Flow	-60.67M
Capital Expenditures	-29.94M
Depreciation & Amortization	20.83M
Net Borrowing	-334.17M
Free Cash Flow	-90.61M
FCF Per Share	-0.01

Margins

Gross margin is 10.12%, with operating and profit margins of 3.04% and 1.24%.

Gross Margin	10.12%
Operating Margin	3.04%
Pretax Margin	1.87%
Profit Margin	1.24%
EBITDA Margin	3.56%
EBIT Margin	3.04%
FCF Margin	n/a

Dividends & Yields

KLSE:PHARMA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-239.34%
Shareholder Yield	-239.34%
Earnings Yield	3.07%
FCF Yield	-5.53%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on July 5, 2021. It was a forward split with a ratio of 5.

Last Split Date	Jul 5, 2021
Split Type	Forward
Split Ratio	5

Scores

Altman Z-Score	n/a
Piotroski F-Score	3